To the full analysis
Revvity stock: growth
RVTYRevvity reported $2.86B in revenue for fiscal 2025, up 3.7% on the prior year, up 1.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.3%
per year from 2006 to 2025, per share 3.8%
Earnings (Annual rate)
3.9%
per year from 2006 to 2025, per share 4.3%
Free cash flow (Annual rate)
10%
per year from 2006 to 2025, per share 10.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −5.5% | 3.1% | 3.3% |
| Revenue per share | −5.8% | 3.0% | 3.8% |
| Earnings | −19.8% | 1.3% | 3.9% |
| Earnings per share | −20.4% | 1.0% | 4.3% |
| Free cash flow | −9.3% | 7.0% | 10.0% |
| Free cash flow per share | −9.6% | 7.0% | 10.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.55B | $117.15M | $82.97M |
| 2007 | $1.79B | $132.92M | $158.15M |
| 2008 | $1.96B | $128.41M | $174.52M |
| 2009 | $1.55B | $85.6M | $117.04M |
| 2010 | $1.7B | $383.92M | $130.61M |
| 2011 | $1.92B | $1.17M | $194.28M |
| 2012 | $2.12B | $68.44M | $109.76M |
| 2013 | $2.17B | $167.92M | $119.6M |
| 2014 | $2.24B | $158.04M | $252.53M |
| 2015 | $2.1B | $212.45M | $257.47M |
| 2016 | $2.12B | $233.68M | $318.91M |
| 2017 | $2.26B | $113.02M | $249.36M |
| 2018 | $2.78B | $238.79M | $217.79M |
| 2019 | $2.88B | $227.56M | $282.14M |
| 2020 | $3.78B | $728.1M | $828.54M |
| 2021 | $3.83B | $943.16M | $1.32B |
| 2022 | $3.31B | $569.18M | $594.18M |
| 2023 | $2.75B | −$118.38M | $9.9M |
| 2024 | $2.76B | $295.83M | $541.65M |
| 2025 | $2.86B | $241.68M | $508.26M |
Revenue by segment
How Revvity, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Life Sciences50%
- Diagnostics50%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Life Sciences | $1.25B | $1.43B | 50.1% |
| Diagnostics | $1.5B | $1.42B | 49.9% |
| Total revenue | $2.76B | $2.86B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Jun 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.